French think-tank warns over UK model

28 May 2009

A French think-tank has published a report examining the potentially "perverse effects" of adopting UK-style health care financing policies  in France under the "loi Bachelot," a reform package currently under  discussion by the National Assembly.

A particular concern of the Institut economique Molinari's paper is the  growing control of physicians by government authorities, including  trying to force newly-qualified doctors to move to underprovided areas.  Guillaume Vuillemey, the report's author, notes that this has the  unintended consequence of making a career in medicine less attractive,  or inciting health care professionals to emigrate, worsening the  shortage in parts of France.

The report examines the role of the National Institute for Health and  Clinical Excellence (NICE), the body that determines which medicines  will be covered by the National Health Service across the UK apart from  Scotland. Mr Vuillemey concludes that the implementation of a similar  system in France would involve restricting access to new drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight